# Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

> **NCT03059446** · PHASE2 · TERMINATED · sponsor: **Tobira Therapeutics, Inc.** · enrollment: 167 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis
- Liver Cirrhosis
- Non-alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Cenicriviroc

## Key facts

- **NCT ID:** NCT03059446
- **Lead sponsor:** Tobira Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-14
- **Primary completion:** 2021-01-05
- **Final completion:** 2021-01-05
- **Target enrollment:** 167 (ACTUAL)
- **Why stopped:** This study was terminated early due to lack of efficacy based on the results of Part I of the AURORA study.
- **Last updated:** 2022-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03059446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03059446, "Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03059446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*